Marksans Pharma (NSE:MARKSANS, BOM:524404), through its UK-based wholly-owned subsidiary Relonchem, has received marketing authorization for its product Ibuprofen and Paracetamol 200 mg/500 mg film-coated tablets, according to a Tuesday filing to the Indian stock exchanges.